JP2019116474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019116474A5 JP2019116474A5 JP2019012878A JP2019012878A JP2019116474A5 JP 2019116474 A5 JP2019116474 A5 JP 2019116474A5 JP 2019012878 A JP2019012878 A JP 2019012878A JP 2019012878 A JP2019012878 A JP 2019012878A JP 2019116474 A5 JP2019116474 A5 JP 2019116474A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- cancer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022063412A JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2024043445A JP2024073610A (ja) | 2010-03-26 | 2024-03-19 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31796410P | 2010-03-26 | 2010-03-26 | |
| US61/317,964 | 2010-03-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061671A Division JP2018117634A (ja) | 2010-03-26 | 2018-03-28 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232781A Division JP2020072681A (ja) | 2010-03-26 | 2019-12-24 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2022063412A Division JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019116474A JP2019116474A (ja) | 2019-07-18 |
| JP2019116474A5 true JP2019116474A5 (https=) | 2020-02-13 |
| JP7100595B2 JP7100595B2 (ja) | 2022-07-13 |
Family
ID=44673895
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501520A Active JP5837567B2 (ja) | 2010-03-26 | 2011-03-25 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2014210674A Active JP6463068B2 (ja) | 2010-03-26 | 2014-10-15 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2016080611A Pending JP2016144468A (ja) | 2010-03-26 | 2016-04-13 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2018061671A Withdrawn JP2018117634A (ja) | 2010-03-26 | 2018-03-28 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2019012878A Active JP7100595B2 (ja) | 2010-03-26 | 2019-01-29 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2019232781A Pending JP2020072681A (ja) | 2010-03-26 | 2019-12-24 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2022063412A Pending JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2024043445A Pending JP2024073610A (ja) | 2010-03-26 | 2024-03-19 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501520A Active JP5837567B2 (ja) | 2010-03-26 | 2011-03-25 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2014210674A Active JP6463068B2 (ja) | 2010-03-26 | 2014-10-15 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2016080611A Pending JP2016144468A (ja) | 2010-03-26 | 2016-04-13 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2018061671A Withdrawn JP2018117634A (ja) | 2010-03-26 | 2018-03-28 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232781A Pending JP2020072681A (ja) | 2010-03-26 | 2019-12-24 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2022063412A Pending JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2024043445A Pending JP2024073610A (ja) | 2010-03-26 | 2024-03-19 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9169328B2 (https=) |
| EP (2) | EP2552959B1 (https=) |
| JP (8) | JP5837567B2 (https=) |
| AU (1) | AU2011230590C1 (https=) |
| CA (4) | CA3255551A1 (https=) |
| DK (1) | DK2552959T3 (https=) |
| ES (1) | ES2621874T3 (https=) |
| HK (1) | HK1244496A1 (https=) |
| HU (1) | HUE032519T2 (https=) |
| ME (1) | ME02670B (https=) |
| PL (1) | PL2552959T3 (https=) |
| PT (1) | PT2552959T (https=) |
| WO (1) | WO2011119979A2 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3255551A1 (en) | 2010-03-26 | 2025-04-15 | Memorial Sloan-Kettering Cancer Center | MUC16 ANTIBODIES AND METHODS OF USE |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| CN113684185A (zh) | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| EP2971044B1 (en) * | 2013-03-13 | 2018-05-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
| BR112016018100A2 (pt) * | 2014-02-07 | 2018-02-20 | Univ Mcmaster | acoplador antigênico de células t trifuncional, métodos e usos do mesmo |
| AU2015218909A1 (en) * | 2014-02-19 | 2016-08-04 | Emergent Biosolutions Canada Inc. | Marburg monoclonal antibodies |
| MX392487B (es) | 2014-10-20 | 2025-03-21 | Juno Therapeutics Inc | Métodos y composiciones para dosificación en terapia celular adoptiva. |
| JP2017537622A (ja) * | 2014-12-02 | 2017-12-21 | ロジャー・ウィリアムズ・ホスピタル | がんを治療するための方法及び組成物 |
| SG11201707538XA (en) | 2015-03-17 | 2017-10-30 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
| CA2981304C (en) | 2015-04-02 | 2024-01-02 | Memorial Sloan Kettering Cancer Center | Tnfrsf14/hvem proteins and methods of use thereof |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| MA54884A (fr) | 2015-07-01 | 2022-01-12 | Immatics Biotechnologies Gmbh | Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| WO2017065203A1 (ja) * | 2015-10-14 | 2017-04-20 | 日本全薬工業株式会社 | イヌアトピー性皮膚炎の治療及び診断のために用いる抗イヌｔａｒｃ抗体 |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| EP3548055A4 (en) | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| SG10202110182PA (en) | 2017-03-15 | 2021-10-28 | Silverback Therapeutics Inc | Benzazepine compounds, conjugates, and uses thereof |
| EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| JP7538601B2 (ja) | 2017-04-26 | 2024-08-22 | ユーリカ セラピューティックス， インコーポレイテッド | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
| CN107557336B (zh) * | 2017-09-15 | 2020-02-14 | 山东兴瑞生物科技有限公司 | 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用 |
| CN111479925B (zh) | 2017-10-12 | 2024-03-08 | 麦克马斯特大学 | 具有y182t突变的t细胞-抗原偶联物及其方法和用途 |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| RU2747095C2 (ru) * | 2018-05-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) | Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125 |
| US11319380B2 (en) * | 2018-06-04 | 2022-05-03 | Precigen, Inc. | MUC16 specific chimeric antigen receptors and uses thereof |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| BR112021001338A2 (pt) * | 2018-07-26 | 2021-05-04 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr usando proteínas de fusão específicas para o alvo |
| MX2021002764A (es) | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. |
| WO2020056192A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Antibody conjugates of toll-like receptor agonists |
| AU2019337654A1 (en) | 2018-09-12 | 2021-04-08 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| WO2020056194A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| JP7632868B2 (ja) * | 2018-10-26 | 2025-02-19 | 国立大学法人信州大学 | 高効率な遺伝子改変細胞の作製方法 |
| CN113366022B (zh) | 2018-11-16 | 2025-11-21 | 纪念斯隆凯特琳癌症中心 | 针对粘蛋白-16的抗体及其使用方法 |
| EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
| EP3966248A4 (en) * | 2019-05-08 | 2023-04-12 | Memorial Sloan Kettering Cancer Center | HUMAN ANTIBODIES TO FEL MUCIN-16 AND THEIR METHODS OF USE |
| WO2021019706A1 (ja) * | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Ｃａｒ発現免疫細胞を含む細胞集団の製造方法 |
| CN114667134A (zh) | 2019-08-15 | 2022-06-24 | 希沃尔拜克治疗公司 | 苯并氮杂䓬缀合物的制剂及其用途 |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| JP2023535371A (ja) | 2020-07-17 | 2023-08-17 | シミュレックス インコーポレイテッド | 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| KR20230122618A (ko) | 2020-12-21 | 2023-08-22 | 알로젠 테라퓨틱스 인코포레이티드 | 프로테아제 활성화 cd45-게이트 car |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| AU2022283819A1 (en) | 2021-06-01 | 2024-01-04 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 t cell-antigen couplers and uses thereof |
| CA3261440A1 (en) | 2022-07-29 | 2024-02-01 | Allogene Therapeutics, Inc. | MODIFIED CELLS WITH REDUCED GENE EXPRESSION TO MITIGATE RECOGNITION BY IMMUNE CELLS |
| IL326412A (en) | 2023-08-11 | 2026-04-01 | Wuxi Biologics Ireland Ltd | Anti-muc16 antibodies and uses thereof |
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| AU2024372734A1 (en) | 2023-10-30 | 2026-04-16 | Allogene Therapeutics, Inc. | Engineered cells |
| CN119978126A (zh) * | 2023-11-10 | 2025-05-13 | 深圳市菲鹏生物治疗股份有限公司 | 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用 |
| TW202523694A (zh) * | 2023-11-17 | 2025-06-16 | 中國大陸商上海藥明生物技術有限公司 | 抗muc16抗體及其用途 |
| WO2025168802A1 (en) | 2024-02-09 | 2025-08-14 | Oslo Universitetssykehus Hf | Chimeric antigen receptor binding to ca125 for treating ovarian cancer |
| CN119638843B (zh) * | 2024-03-20 | 2025-08-26 | 武汉勖瑞生物科技有限责任公司 | 一种抗ca125蛋白的单克隆抗体及其应用 |
| CN118791617B (zh) * | 2024-07-02 | 2025-03-07 | 安徽德合功生物科技有限公司 | Ca125单克隆抗体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US505713A (en) | 1893-09-26 | Thomas j | ||
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| AU5554190A (en) | 1989-05-08 | 1990-11-29 | Mark I. Farber | Process and apparatus for the recovery of precious metals from slag, tailings and other materials |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5976818A (en) * | 1991-12-16 | 1999-11-02 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| WO1995021381A1 (en) | 1994-02-01 | 1995-08-10 | The Rockefeller University | Methods and agents for measuring and controlling multidrug resistance |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| CU22731A1 (es) | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
| US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| JP2003530819A (ja) | 1999-06-14 | 2003-10-21 | ノボ ノルディスク アクティーゼルスカブ | ＦＶＩＩａ／ＴＦ活性阻害化合物 |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| CA2388063C (en) | 1999-11-24 | 2010-06-08 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| US6905839B2 (en) | 2002-07-31 | 2005-06-14 | Takashi Furuta | In vivo phenotyping for human cytochrome P450 3A activity |
| GB2395270B (en) * | 2002-11-14 | 2006-08-16 | Univ Nottingham | Tumour marker proteins and uses thereof |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| EP1723178A4 (en) | 2004-03-12 | 2007-12-12 | Human Genome Sciences Inc | HUMAN G-PROTEIN CHEMOKIN RECEPTOR (CCR5) HDGNR10 |
| CA2566498A1 (en) | 2004-05-14 | 2005-12-08 | The Regents Of The University Of California | Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| PL2135881T3 (pl) | 2005-06-20 | 2012-02-29 | Genentech Inc | Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| CA3255551A1 (en) | 2010-03-26 | 2025-04-15 | Memorial Sloan-Kettering Cancer Center | MUC16 ANTIBODIES AND METHODS OF USE |
| US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
| JP2016523961A (ja) | 2013-07-09 | 2016-08-12 | ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ ネブラスカＢｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｅｂｒａｓｋａ | 癌を治療するための糖タンパク質の標的化方法 |
| SG11201707538XA (en) | 2015-03-17 | 2017-10-30 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
-
2011
- 2011-03-25 CA CA3255551A patent/CA3255551A1/en active Pending
- 2011-03-25 US US13/635,090 patent/US9169328B2/en active Active
- 2011-03-25 ES ES11760326T patent/ES2621874T3/es active Active
- 2011-03-25 JP JP2013501520A patent/JP5837567B2/ja active Active
- 2011-03-25 ME MEP-2017-89A patent/ME02670B/me unknown
- 2011-03-25 CA CA3188287A patent/CA3188287C/en active Active
- 2011-03-25 WO PCT/US2011/030025 patent/WO2011119979A2/en not_active Ceased
- 2011-03-25 CA CA2793753A patent/CA2793753C/en active Active
- 2011-03-25 DK DK11760326.6T patent/DK2552959T3/en active
- 2011-03-25 HU HUE11760326A patent/HUE032519T2/en unknown
- 2011-03-25 EP EP11760326.6A patent/EP2552959B1/en active Active
- 2011-03-25 CA CA3002192A patent/CA3002192C/en active Active
- 2011-03-25 EP EP17150631.4A patent/EP3222632A1/en active Pending
- 2011-03-25 AU AU2011230590A patent/AU2011230590C1/en active Active
- 2011-03-25 PT PT117603266T patent/PT2552959T/pt unknown
- 2011-03-25 PL PL11760326T patent/PL2552959T3/pl unknown
-
2014
- 2014-10-15 JP JP2014210674A patent/JP6463068B2/ja active Active
-
2015
- 2015-09-10 US US14/850,675 patent/US9790283B2/en active Active
-
2016
- 2016-04-13 JP JP2016080611A patent/JP2016144468A/ja active Pending
-
2017
- 2017-09-05 US US15/695,311 patent/US10759869B2/en active Active
-
2018
- 2018-03-23 HK HK18104038.6A patent/HK1244496A1/en unknown
- 2018-03-28 JP JP2018061671A patent/JP2018117634A/ja not_active Withdrawn
-
2019
- 2019-01-29 JP JP2019012878A patent/JP7100595B2/ja active Active
- 2019-12-24 JP JP2019232781A patent/JP2020072681A/ja active Pending
-
2020
- 2020-07-28 US US16/941,348 patent/US11834513B2/en active Active
-
2022
- 2022-04-06 JP JP2022063412A patent/JP2022088649A/ja active Pending
-
2024
- 2024-03-19 JP JP2024043445A patent/JP2024073610A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019116474A5 (https=) | ||
| JP7562528B2 (ja) | 抗体及びその用途 | |
| JP7150880B2 (ja) | 抗－ｂ７－ｈ３抗体およびその用途 | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| CN107840887B (zh) | 一种新的pd-1单克隆抗体 | |
| JP2019519492A5 (https=) | ||
| JP2020510422A5 (https=) | ||
| CN112154157A (zh) | 抗ror1抗体及其用途 | |
| JP2021503455A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| IL302278A (en) | Combination treatment | |
| US20240301085A1 (en) | Humanized gpc3 antibody and application thereof | |
| KR20160127825A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
| US20240117035A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| JP2024001073A5 (https=) | ||
| RU2018102803A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2021517152A5 (https=) | ||
| JP2023524102A5 (https=) | ||
| JP2022513050A5 (https=) | ||
| CN114641504A (zh) | 抗b7h4抗体及其双抗和应用 | |
| CN119213023A (zh) | Ilt3和cd3结合剂以及其使用方法 | |
| JP2023517754A (ja) | 抗ｍｕｃ１－ｓｅａ抗体 | |
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| JP2021529524A5 (https=) | ||
| JP2024509501A5 (https=) |